| Dr Denise Ann Morris, MD | |
|
2005 C Pioneer St, Waycross, GA 31501 | |
| (912) 284-9888 | |
| (912) 285-8533 |
| Full Name | Dr Denise Ann Morris |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine - Endocrinology, Diabetes & Metabolism |
| Location | 2005 C Pioneer St, Waycross, Georgia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104999226 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | 035482 (Georgia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Denise Ann Morris, MD 2005 C Pioneer St, Waycross, GA 31501 Ph: (912) 284-9888 | Dr Denise Ann Morris, MD 2005 C Pioneer St, Waycross, GA 31501 Ph: (912) 284-9888 |
News Archive
PhaseBio Pharmaceuticals, Inc., a privately held, clinical-stage biotechnology company developing drugs to treat diabetes, metabolic disease and cardiovascular disease, announced today that it has initiated dosing in a multicenter (USA), randomized, placebo and active comparator controlled Phase 2b study that will enroll approximately 600 patients with type 2 diabetes (hemoglobin A1c 7% - 11%) inadequately controlled with diet and exercise, metformin, a sulfonylurea or a combination of metformin/sulfonylurea.
IXYS Corporation announced today that its Board of Directors has authorized an additional stock repurchase program of up to 1,000,000 shares of its common stock, or approximately 3% of the Company's approximately 31 million shares of common stock currently outstanding.
Congressional Republicans want to know whom she contacted and what other HHS officials are involved, while Sen. Lamar Alexander said he would ask the Government Accountability Office to investigate. A Sebelius spokesman said her actions were legal, and that she had not solicited pharmaceutical and insurance companies regulated by the agency.
AVEO Pharmaceuticals, Inc., today announced data from the final analysis of its Phase 2 randomized discontinuation trial evaluating tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with advanced renal cell carcinoma.
A groundbreaking study led by engineering and medical researchers at the University of Minnesota Twin Cities shows how engineered immune cells used in new cancer therapies can overcome physical barriers to allow a patient's own immune system to fight tumors.
› Verified 3 days ago
Dr. Prasanna Sampurna Srinagesh, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 220 Uvalda St, Waycross, GA 31501 Phone: 912-285-2053 | |
James Clark, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1409 Satilla Blvd, Waycross, GA 31501 Phone: 912-816-3455 | |
Dr. Charles Galea, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 615-a Pendleton Street, Waycross, GA 31501 Phone: 912-548-0710 Fax: 912-548-0071 | |
David A Rios, PA Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 808 Beacon St, Waycross, GA 31501 Phone: 912-490-4325 Fax: 912-490-7673 | |
Dr. Jawad Sheqwara, M.D Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1706 Alice St, Waycross, GA 31501 Phone: 912-490-4673 Fax: 912-490-4674 | |
Dr. Jill G Bryant, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 711 Knight Ave, Waycross, GA 31501 Phone: 912-283-9423 Fax: 912-283-8204 |